Skip to main content

Leukemia, lymphoma, and myeloma.

83 Phase 1 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Leukemia, lymphoma, and myeloma83 studies

Relapsed/Refractory B-Cell LymphomaPhase 1/2NCT03223610Papers

ViPOR Combination

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Cancer Institute (NCI)Open the brief

B-Non Hodgkin LymphomaPhase 1/2NCT05442515Papers

CD19/CD22-CAR-transduced T cells

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

National Cancer Institute (NCI)Open the brief

Hairy Cell LeukemiaPhase 1NCT04815356Papers

CD22CART cell

Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

National Cancer Institute (NCI)Open the brief

Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromePhase 1NCT05986240

Danvatirsen

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Montefiore Medical CenterOpen the brief

Hodgkin's LymphomaPhase 1NCT02917083Papers

CAR T Cells

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Baylor College of MedicineOpen the brief

Large B-cell LymphomaPhase 1NCT07052305

NT-I7 after CAR T for large B-cell lymphoma

NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of MedicineOpen the brief

Relapsed or Refractory Post-Transplant Lymphoproliferative DisorderPhase 1NCT06672705

Epcoritamab

Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders

Timothy VoorheesOpen the brief

Relapsed/Refractory Acute Myeloid LeukemiaPhase 1NCT03874052Papers

Ruxolitinib + Venetoclax

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Jennifer SaultzOpen the brief

Acute Myeloid LeukemiaPhase 1/2NCT03214562Papers

Venetoclax

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

M.D. Anderson Cancer CenterOpen the brief

Relapsed or Refractory AML, MDS or CMMLPhase 1NCT04375631

CLAG-M or FLAG-Ida + Total Body Irradiation Before Transplant

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Fred Hutchinson Cancer CenterOpen the brief

Non Hodgkin LymphomaPhase 1NCT07225439Papers

Tafasitamab

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Paolo Caimi, MDOpen the brief

Relapsed or Refractory Acute Myeloid LeukemiaPhase 1NCT07025564Papers

miRisten (miR-126 Inhibitor)

MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

City of Hope Medical CenterOpen the brief

Clinical trials: Phase 1 and Phase 2, explained